Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials

What's known on the subject? and What does the study add?

[1]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[2]  T. Choueiri,et al.  Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy , 2011, Cancer.

[3]  D. Doval,et al.  Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Motzer,et al.  Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Motzer,et al.  Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Porta,et al.  Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial , 2011, British Journal of Cancer.

[7]  B. Rini,et al.  AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Burke,et al.  Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Philippe P Roux,et al.  [mTOR, the mammalian target of rapamycin]. , 2010, Medecine sciences : M/S.

[10]  A. Armstrong,et al.  Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). , 2010 .

[11]  J. Bay,et al.  Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. , 2010 .

[12]  A. Ravaud,et al.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[14]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Motzer,et al.  Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis , 2010, British Journal of Cancer.

[16]  P. Tamboli,et al.  Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low‐dose interferon alfa in patients with advanced renal cell carcinoma , 2009, Cancer.

[17]  M. Neary,et al.  7119 Genitourinary malignancies – Renal cancer Quality of life (QOL) in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind, placebo-controlled trial , 2009 .

[18]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Chacko,et al.  Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Cella,et al.  Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Porta,et al.  257 UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA , 2009 .

[23]  R. Figlin,et al.  Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies , 2009, Medical oncology.

[24]  E. Small,et al.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[26]  Frank Pétavy,et al.  Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Wilt,et al.  Targeted therapy for advanced renal cell carcinoma. , 2008, The Cochrane database of systematic reviews.

[28]  R. Figlin,et al.  Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[29]  A. Ravaud,et al.  Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. , 2007, The Journal of urology.

[30]  R. Figlin,et al.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Porta,et al.  Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681 , 2007 .

[32]  D. Cella,et al.  Effects of Sorafenib on Symptoms and Quality of Life: Results From a Large Randomized Placebo-Controlled Study in Renal Cancer , 2007, American journal of clinical oncology.

[33]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[34]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Gore,et al.  Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Srinivas,et al.  A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma , 2005, BJU international.

[37]  G. Rosner,et al.  Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Harris,et al.  A randomised phase II study of interferon alpha alone or in combination with thalidomide in metastatic renal cancer , 2004 .

[39]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[41]  C. Porta,et al.  Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial , 2008 .

[42]  C. Porta,et al.  Rapsody: randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α 2A (IFN) in metastatic renal cell carcinoma (MRCC). GOIRC study 0681 , 2007 .